

# **PhRMA Adaptive Design Workshop**

**Nov 13-14, 2006**

---

**Michael Krams, MD, Wyeth (Co-Chair)**

**Walt Offen, PhD, Lilly, (Co-Chair)**

---

**Marriott Bethesda**

**North Hotel**

---

**Slides available at....**

---

- **Innovation.org**

# Workshop Program Committee

---

Michael Krams, MD, Wyeth (Co-Chair)

Walt Offen, PhD, Eli Lilly (Co-Chair)

Dennis Erb, Merck and Co., Inc.

Brenda Gaydos, PhD, Eli Lilly and Company

Frank Shen, PhD, Bristol-Myers Squibb Company

Luc Truyen, MD, PhD, Johnson & Johnson

Greg Campbell, PhD, FDA

Shirley Murphy, MD, FDA

Robert O'Neill, PhD, FDA

Robert Powell, PharmD, FDA

Marc Walton, MD, PhD, FDA

Sue Jane Wang, PhD, FDA

# Special Thanks

---

**Karen Bruun (PbRMA)**  
**Michael Krams (Wyeth)**

**Bob O'Neill**

**(FDA)**

# **Workshop Outline – Day 1**

---

- **9:30-10:15: Presidential Debate**
- **3:45-5:15: Who sees unblinded interim data?**
- **5:15-6:15: Dr. Henry Lee, forensic scientist**
- **6:15-7:15: Reception**

# **Workshop Outline – Day 2**

---


- **8:30-10:00: Regulatory**
- **10:15-Noon: Breakouts**
  - **Crossover–2 sessions(10:15-11:05; 11:10-Noon)**
  - **Intent is to maximize audience participation**
- **1:00-1:50: Plenary session (Drs. Berry & Grieve)**
- **2:30-3:30: Next Steps Panel**

# Workshop Goal


---

- 1. Identify approaches and methodology which retain scientific integrity of study**
  - 2. Identify those that do not**
  - 3. Identify those that require case-by-case consideration by regulators**
- Determine how to move issues in the gray zone (bucket #3) to #1 or #2**

# Upper Level Map




# Lower Level Map



# Time

---

- **Session chairs:**  
**Please synchronize your watches:**  
**It is now: ....8.3X am**
- **Very important:**  
**We need to stick to allotted time**





3

minute



1

minute

0

minute

Stop Now!!

Please

You're killing me!

-1

minute

Stop Now!!

Please

You're killing me!

-1

minute

1 minute to John Tesh!

# Definition of “Adaptive Design”

---

- **A clinical study design that uses accumulating data to decide how to modify aspects of the study as it continues, without undermining the validity and integrity of the trial**
  - **Definition is broad – not classified by statistical methodology or approach**
  - **Traditional interim analysis where one may stop early to declare efficacy is a type of adaptive design**

# Spectrum of Blinding


Bias Control

Very Low


Very High



# Spectrum of Blinding



# Spectrum of Blinding



# Spectrum of Blinding

